The New Paper

April 21, 2021

Johnson and Johnson resumes European vaccine rollout

Johnson & Johnson announced plans to resume shipments of its coronavirus vaccine in Europe following a review by the European Medicines Agency. The EMA found that unusual blood clots should be listed as a “very rare” side effect of the vaccine and that the overall benefits outweigh the risks.
This story is from the April 21, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.